And in line with the initial discovery that MYO18B is silenced by hypermethylation of its promoter in lung cancers (Nishioka et al., 2002), hypermethylation of MYO18B promoter was found to be associated with weaker response to chemotherapies in ovarian cancers (Tomar et al., 2017), whereas hypomethylation of its promoter is associated with high MYO18B expression and favorable outcomes of T-cell acute leukemia cases (Haider et al., 2019). Here, MYO18B is linked to ovarian carcinoma.